Suppr超能文献

患者和临床医生报告的乳腺癌急性放射性皮炎结局的一致性。

Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer.

机构信息

Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

MacroStat Inc, Toronto, ON, Canada.

出版信息

Support Care Cancer. 2024 Nov 4;32(11):767. doi: 10.1007/s00520-024-08966-6.

Abstract

BACKGROUND AND PURPOSE

The study evaluated the concordance between patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) of acute radiation dermatitis (RD) symptoms following adjuvant radiotherapy for early-stage and locally advanced breast cancer.

MATERIAL AND METHODS

This is a secondary analysis of a multi-center randomized phase 3 trial (376 patients). Ordinal logistic regression analysis was used to compare the Skin Symptom Assessment (SSA) independently reported by both patients and clinicians. Concordance between patient- and clinician-reported SSAs for RD symptoms was measured by percent concordance, concordance index (C-statistic), and Cohen's Kappa. Analyses were performed across all patients in the original modified intention-to-treat analysis and those with only grade 2-3 (CTCAE) RD.

RESULTS

PROs were significantly more severe than CROs across all RD symptoms (Odds Ratio [OR] > 1; p < 0.0001). Pigmentation (OR 5.4), blistering/peeling (OR 4.0), and pain/soreness (OR 3.9) were the most differentially reported symptoms. Poor-to-low concordance was noted between patient- and clinician-reported SSAs for all RD symptoms for the entire cohort (percent concordance < 50%, C-statistic 0.52-0.63, Cohen's Kappa 13.9-23.4%) and those with grade 2-3 RD (percent concordance < 50%, C-statistic 0.56-0.66, Cohen's Kappa 2.0-24.5%). Similarly, poor-to-low concordance was noted in both Mepitel film and standard-of-care arms.

CONCLUSION

PROs and CROs have poor concordance in breast RD, and patients report worse outcomes than clinicians, regardless of RD severity or prophylaxis. PROs must be further integrated into routine clinical practice and clinical trial design to reduce the risk of underreporting symptoms.

摘要

背景与目的

本研究评估了辅助放疗治疗早期和局部晚期乳腺癌后急性放射性皮炎(RD)症状的患者报告结局(PRO)和临床医生报告结局(CRO)之间的一致性。

材料与方法

这是一项多中心随机 3 期试验(376 例患者)的二次分析。使用有序逻辑回归分析比较了患者和临床医生独立报告的皮肤症状评估(SSA)。使用百分比一致性、一致性指数(C 统计量)和 Cohen's Kappa 测量 RD 症状的患者和临床医生报告的 SSA 之间的一致性。在原始改良意向治疗分析的所有患者以及仅 2-3 级(CTCAE)RD 的患者中进行了分析。

结果

所有 RD 症状的 PRO 均显著重于 CRO(优势比 [OR] > 1;p < 0.0001)。色素沉着(OR 5.4)、水疱/脱皮(OR 4.0)和疼痛/酸痛(OR 3.9)是报告差异最大的症状。整个队列中,所有 RD 症状的患者和临床医生报告的 SSA 之间的一致性较差(百分比一致性<50%,C 统计量 0.52-0.63,Cohen's Kappa 13.9-23.4%)和那些 2-3 级 RD(百分比一致性<50%,C 统计量 0.56-0.66,Cohen's Kappa 2.0-24.5%)。同样,在 Mepitel 膜和标准护理臂中也观察到了较差的一致性。

结论

无论 RD 严重程度或预防措施如何,PRO 和 CRO 在乳房 RD 中一致性较差,且患者报告的结局比临床医生更差。必须进一步将 PRO 纳入常规临床实践和临床试验设计中,以降低症状报告不足的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验